Compare SFHG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFHG | CMMB |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 8.4M |
| IPO Year | 2022 | 2023 |
| Metric | SFHG | CMMB |
|---|---|---|
| Price | $2.05 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 4.8K | ★ 27.6K |
| Earning Date | 09-29-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $28.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.92 |
| 52 Week High | $3.17 | $2.99 |
| Indicator | SFHG | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 35.77 |
| Support Level | $1.98 | $1.05 |
| Resistance Level | $2.17 | $1.91 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 20.99 | 52.86 |
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.